ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

In the UK, both media and public attention are focused on sildenafil [‘Viagra’; Pfizer]. Secretary of State for Health Frank Dobson has announced which patient groups will qualify for impotence treatments, including ‘Viagra’, on the National Health Service (NHS), effective from 1 July 1999.*Other patients not included in this restrictive prescribing list will be able to get sildenafil from specialists but only in ‘exceptional cases of extreme distress’, according to the UK Department of Health. Perhaps prompting this type of decision is the fact that ‘Viagra’ is classified as a ‘lifestyle medicine’ - an intervention for a condition that in itself is not life-threatening. Also, the NHS is worried about the potential for high patient demand for the oral erectile dysfunction (ED) therapy.1

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

Interest is growing over the potential to prevent breast cancer, after last year's exciting results showing that tamoxifen reduces the incidence of breast cancer in women at high risk for the disease. New data presented at the 90th Annual Meeting of the American Association for Cancer Research [Philadelphia, US; April 1999] show that the synthetic retinoid fenretinide [4-HPR] reduces the incidence of contralateral breast cancer and local recurrence of breast cancer in premenopausal women with stage 1 disease.

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS